4 results
To compare progression-free survival (PFS) in patients who receive RAD0901 plus Best Supportive Care (BSC) versus patients who receive Matching Placebo plus BSC.
To determine whether treatment with RAD001 10 mg/d plus best supportive care prolongs the progression free survival (PFS) compared to treatment with Placebo plus best supportive care in patients with advanced pancreatic neuroendocrine tumor.
PART I:Primary:• To investigate the safety and tolerability of two doses of VAD044 administered daily for up to 12 weeks in HHT patients.Secondary:• To assess the effects of two doses of VAD044 for up to 12 weeks of treatment on:o Epistaxis:•…
To assess the effect of BLU-5937 vs placebo on 24-hour cough frequencyin adults with RCC (including unexplained chronic cough) and Baseline24-hourcough frequency >=8 coughs/h at Week 12.To determine the safety of BLU-5937 vs placebo in adults…